Agios Pharmaceuticals (FRA:8AP) Cyclically Adjusted Book per Share: €14.40 (As of Mar. 2026)


FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
46 GF Score
Price €33.20
GF Value €75.15
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Cyclically Adjusted Book per Share?

Agios Pharmaceuticals FRA:8AP 46 Cyclically Adjusted Book per Share is €14.40 as of Mar. 2026. GuruFocus rates FRA:8AP with a GF Score™ of 46/100 and a GF Value™ of €75.15 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Agios Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €35.436. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €14.40 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Agios Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 11.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 10.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Agios Pharmaceuticals was 14.10% per year. The lowest was 10.80% per year. And the median was 12.45% per year.

As of today (2026-07-01), Agios Pharmaceuticals's current stock price is €33.20. Agios Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €14.40. Agios Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 2.31.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Agios Pharmaceuticals was 3.81. The lowest was 1.34. And the median was 1.95.


Agios Pharmaceuticals  (FRA:8AP) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Agios Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=33.20/14.40
=2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Agios Pharmaceuticals was 3.81. The lowest was 1.34. And the median was 1.95.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Agios Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Agios Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Cyclically Adjusted Book per Share Chart

Agios Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.02 11.84 13.70 15.87 15.06

Agios Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.98 15.11 14.61 15.06 14.40

FRA:8AP vs ABCL, KOD, IMNM: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Agios Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:8AP
46GF Score
Agios Pharmaceuticals Inc FRA:8AP
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agios Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agios Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=35.436/330.2130*330.2130
=35.436

Current CPI (Mar. 2026) = 330.2130.

Agios Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 6.765 241.018 9.269
201609 8.514 241.428 11.645
201612 8.052 241.432 11.013
201703 6.781 243.801 9.184
201706 9.370 244.955 12.631
201709 7.762 246.819 10.385
201712 6.499 246.524 8.705
201803 12.200 249.554 16.143
201806 12.162 251.989 15.937
201809 11.200 252.439 14.651
201812 10.381 251.233 13.644
201903 9.358 254.202 12.156
201906 8.024 256.143 10.344
201909 6.913 256.759 8.891
201912 8.428 256.974 10.830
202003 8.226 258.115 10.524
202006 7.181 257.797 9.198
202009 5.895 260.280 7.479
202012 4.739 260.474 6.008
202103 27.634 264.877 34.450
202106 23.854 271.696 28.992
202109 21.668 274.310 26.084
202112 21.044 278.802 24.925
202203 20.015 287.504 22.988
202206 19.399 296.311 21.619
202209 19.322 296.808 21.497
202212 18.880 296.797 21.006
202303 17.431 301.836 19.070
202306 15.968 305.109 17.282
202309 14.870 307.789 15.953
202312 13.293 306.746 14.310
202403 12.060 312.332 12.750
202406 10.789 314.175 11.340
202409 25.703 315.301 26.919
202412 25.747 315.605 26.939
202503 23.434 319.799 24.197
202506 20.459 322.561 20.944
202509 18.776 324.800 19.089
202512 17.433 324.054 17.764
202603 35.436 330.213 35.436

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €14.40 mean?
Agios Pharmaceuticals (FRA:8AP) has a Cyclically Adjusted Book per Share of €14.40 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Agios Pharmaceuticals' current Cyclically Adjusted Book per Share is €14.40. Overall, Agios Pharmaceuticals has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Cyclically Adjusted Book per Share compare to ABCL and KOD?
Agios Pharmaceuticals' Cyclically Adjusted Book per Share of €14.40 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Cyclically Adjusted Book per Share is €14.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (FRA:8AP) is currently considered Possible Value Trap. The stock's GF Value™ is €75.15, compared to a current price of €33.20 — trading 55.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is €14.40. Agios Pharmaceuticals' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Cyclically Adjusted Book per Share is €14.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €33.20 is trading 55.8% below its estimated GF Value™ of €75.15. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:8AP:

  • Cyclically Adjusted Book per Share: €14.40
  • GF Value™: €75.15 vs. price of €33.20 (55.8% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
46GF Score

Get the complete analysis for FRA:8AP

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.20
Price
€75.15
GF Value